Anticancer Drugs Oncology Pharmacology Physiotherapy

Trametinib and RVO

In this article we will discuss Trametinib and RVO

In this article, we will discuss Trametinib and RVO. So, let’s get started.

Retinal Vein Occlusion (RVO)

Across clinical trials with Trametinib, the incidence of RVO was 0.2%. RVO may lead to macular edema, decreased visual function, neovascularization, and glaucoma.
Urgently (within 24 hours) perform ophthalmological evaluation for patient-reported loss of vision or other
visual disturbances. Permanently discontinue Trametinib in patients with documented RVO.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.